Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):112–114. doi: 10.1038/bjc.1993.295

Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids.

T J Hursti 1, M Fredrikson 1, G Steineck 1, S Börjeson 1, C J Fürst 1, C Peterson 1
PMCID: PMC1968293  PMID: 8318400

Abstract

Lower pre-chemotherapy night time cortisol excretion predicted more severe cisplatin induced nausea and vomiting in 42 ovarian cancer patients receiving ondansetron as a single antiemetic agent. Dexamethasone administration added to the antiemetic effect of ondansetron principally in patients who had low excretion of cortisol.

Full text

PDF
112

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cassileth P. A., Lusk E. J., Torri S., DiNubile N., Gerson S. L. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med. 1983 Jul;143(7):1347–1349. [PubMed] [Google Scholar]
  2. Coleman R. E., Twelves C. J., O'Reilly S. M., Rubens R. D., Richards M. A., Harper P. G. Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting. Eur J Cancer. 1991;27(8):1062–1063. doi: 10.1016/0277-5379(91)90286-m. [DOI] [PubMed] [Google Scholar]
  3. Fredrikson M., Hursti T., Fürst C. J., Steineck G., Börjeson S., Wikblom M., Peterson C. Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer. 1992 May;65(5):779–780. doi: 10.1038/bjc.1992.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Greenland S., Robins J. M. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985 Mar;41(1):55–68. [PubMed] [Google Scholar]
  5. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Cirrincione C., Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989 Jan;7(1):108–114. doi: 10.1200/JCO.1989.7.1.108. [DOI] [PubMed] [Google Scholar]
  6. Livrea P., Trojano M., Simone I. L., Zimatore G. B., Logroscino G. C., Pisicchio L., Lojacono G., Colella R., Ceci A. Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol. 1985;231(6):336–339. doi: 10.1007/BF00313712. [DOI] [PubMed] [Google Scholar]
  7. Sagar S. M. The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control. Cancer Treat Rev. 1991 Jun;18(2):95–135. doi: 10.1016/0305-7372(91)90009-o. [DOI] [PubMed] [Google Scholar]
  8. Smith D. B., Newlands E. S., Rustin G. J., Begent R. H., Howells N., McQuade B., Bagshawe K. D. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991 Aug 24;338(8765):487–490. doi: 10.1016/0140-6736(91)90555-4. [DOI] [PubMed] [Google Scholar]
  9. Young S. N. Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacol. 1981 Nov;74(3):695–700. doi: 10.1111/j.1476-5381.1981.tb10480.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES